Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

4.590 +0.080 (+1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
Verve Therapeutics (VERV) stock is taking a beating on Monday following bad news from the U.S. Food and Drug Administration (FDA). 
Via InvestorPlace
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Mixed; Dow Rises Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 50 points on Monday. 
Via Benzinga
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
Verve Therapeutics hopes to use a next-generation form of CRISPR called base editing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
The company is testing a CRISPR-based approach to high cholesterol. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! We're diving into the biggest pre-market stock movers for Monday as we get ready for another week of trading! 
Via InvestorPlace
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022 
From Verve Therapeutics
Via GlobeNewswire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
Via Benzinga
Cathie Wood Just Bought the TSLA Stock Dip. Should You?
Cathie Wood is doubling down on TSLA stock. Here's why investors may want to follow her lead before markets shift in 2023. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
5 Top Stocks Cathie Wood Is Buying This Week
There's a new Ark fund in town, and its name is the ARK Venture Fund. It will capitalize on democratizing private investments to the public. 
Via InvestorPlace
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Amazon, bluebird bio And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Cathie Wood Loads Up $23M Worth Of Shares In This Gene-Editing Company As Stock Falls Over 10% In A Month
Cathie Wood-led Ark Investment Management on Friday raised its stake in clinical stage genetics medicine company Verve Therapeutics Inc (NASDAQ: VERV) via two of its exchange-traded funds. 
Via Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
5 Top Stocks Cathie Wood Is Buying Right Now
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies. 
Via InvestorPlace
FedEx, NCR, International Paper And Other Big Losers From Friday
U.S. stocks closed lower with the Nasdaq Composite dropping over 100 points on Friday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday. 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Salesforce To $250? Here Are 5 Other Price Target Changes For Thursday
Credit Suisse cut the price target on Salesforce, Inc. (NYSE: CRM) from $315 to $250. Credit Suisse analyst Phil Winslow maintained the stock with an Outperform rating. Salesforce shares fell 6.4% to... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.